Pre-Exposure Prophylaxis for the Prevention of HIV Infection in High Risk Populations: A Meta-Analysis of Randomized Controlled Trials

Junjun Jiang1,2,9, Xiaoyi Yang1,2,9, Li Ye1,2, Bo Zhou1, Chuanyi Ning1,2, Jiegang Huang1,2, Bingyu Liang1,2, Xiaoni Zhong3, Ailong Huang3, Renchuan Tao3, Cunwei Cao3, Hui Chen4, Zhao Cheng5, Hao Liang1,2*

1 Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Medical University, Nanning, Guangxi, China, 2 School of Public Health, Guangxi Medical University, Nanning, Guangxi, China, 3 School of Public Health, Chongqing Medical University, Chongqing, China, 4 Geriatrics Digestion Department of Internal Medicine, The First Affiliated Hospital of GuangXi Medical University, Nanning, Guangxi, China

**Background:** Nearly ten randomized controlled trials (RCTs) of pre-exposure prophylaxis (PrEP) have been completed or are ongoing worldwide to evaluate the effectiveness of PrEP in HIV transmission among HIV-uninfected high risk populations. The purpose of this study was to evaluate the role of PrEP to prevent HIV transmission through a Meta-analysis.

**Methods:** A comprehensive computerized literature search was carried out in PubMed, EMBase, Ovid, Web of Science, Science Direct, Wan Fang, CNKI and related websites to collect relevant articles (from their establishment date to August 30, 2013). The search terms were “pre-exposure prophylaxis”, “high risk population”, “HIV infection”, “reduction”, “relative risk” and “efficacy”. We included any RCT assessing PrEP for the prevention of HIV infection in high risk populations. Interventions of the studies were continuously daily or intermittent doses of single or compound antiretrovirals (ARVs) before HIV exposure or during HIV exposure. A meta-analysis was conducted using Stata 10.0. A random-effects method was used to calculate the pooled relative risk (RR) and 95% confidence intervals (CI) for all studies included.

**Results:** Seven RCTs involving 14,804 individuals in high risk populations were eligible for this study. The number of subjects in the experimental groups was 8,195, with HIV infection rate of 2.03%. The number of subjects in the control groups was 6,609, with HIV infection rate of 4.07%. The pooled RR was 0.53 (95% CI = 0.40–0.71, P = 0.001). The re-analyzed pooled RR were 0.61 (95% CI = 0.48–0.77, P < 0.001), 0.49 (95% CI = 0.38–0.63, P < 0.001), respectively, by excluding the largest study or two studies without statistical significance. Publication bias analysis revealed a symmetry funnel plot. The fail-safe number was 1,022.

**Conclusion:** These results show that PrEP is an effective strategy for reducing new HIV infections in high risk populations.

**Introduction**

Thirty years after HIV/AIDS was first identified as a serious disease, more than 60 million people have been infected with HIV and approximately 30 million people have died of AIDS. HIV remains a significant global health problem and a huge burden for our society. At the end of 2011, there were an estimated 34.0 (31.4–35.9) million people living with HIV/AIDS globally, with 2.5 (2.2–2.8) million new HIV infections [1]. The number of people infected with HIV will continue to increase unless effective interventions are established. Previous interventions to prevent HIV infection were largely dependent on male-controlled methods (male condoms, male circumcision and abstinence). However, more than 90% of all adolescent and adult HIV infections worldwide have resulted from heterosexual sex behaviors. Women are more vulnerable to heterosexual transmission of HIV due to substantial mucosal exposure to seminal fluids as well as social and biological factors [2,3]. A series of unwilling interventions have highlighted the need for behavioral strategies to accompany biomedical strategies, especially for women to protect themselves against HIV infection. Therefore, female-controlled prevention has been proposed as a novel strategy to fill this gap.

Traditional interventions have been known to be poorly effective in HIV prevention. It is important to include new approaches to prevent HIV transmission, for example pre-exposure prophylaxis (PrEP). Recently, the prophylactic use of ARVs in preventing the sexual transmission of HIV, both orally and topically, has shown great promise [4,5]. PrEP refers to the use of one or a combination of ARVs in HIV-negative individuals to prevent HIV infection [6–8]. In 2001, the nucleotide reverse transcriptase inhibitor tenofovir disoproxil fumarate (TDF) was approved for clinical therapy of HIV/AIDS. And then the combination of tenofovir and emtricitabine (TDF/FTC) was approved in 2004 [9]. In the absence of an effective vaccine at present, PrEP might be a reliable intervention to protect high risk HIV-negative people from HIV infection [10–13].

---

**Citation:** Jiang J, Yang X, Ye L, Zhou B, Ning C, et al. (2014) Pre-Exposure Prophylaxis for the Prevention of HIV Infection in High Risk Populations: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE 9(2): e87674. doi:10.1371/journal.pone.0087674

**Editor:** Patricia Kissinger, Tulane University, United States of America

**Received:** October 24, 2013; **Accepted** December 28, 2013; **Published** February 3, 2014

**Copyright:** © 2014 Jiang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This study was supported by National Key Science and Technology Project (Grant Number 2008ZX10001016 and 2012ZX10001007-007). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

* E-mail: chenhui680804@163.com (HC); haolphd@163.com (HL)

† These authors contributed equally to this work.
Animal studies have shown that daily or intermittent PrEP with TDF/FTC can exploit early viral vulnerabilities and effectively prevent HIV infection [14–16]. Mathematical models estimate that, over the next 10 years, an effective PrEP program could prevent 2.7–3.2 million new HIV-1 infections in sub-Saharan Africa [17,18]. Model simulations have also shown that an effective PrEP program could substantially reduce the incidence of HIV transmission in populations at high risk of infection [9,19]. A review of clinical randomized controlled trials (RCTs) has indicated the important protective effects of oral antiretroviral drugs in the Cochrane Collaboration [20]. However, this review only included various types of oral PrEP in 9049 participants, and did not include studies involving topical application of ARVs (e.g., vaginal gels). Since then, RCTs have been initiated in multiple high risk populations with standard dosing of ARVs. However, there has been no meta-analysis of the role of PrEP in HIV prevention, both orally and topically. Therefore, this study evaluates the effectiveness of PrEP in preventing HIV infection in high risk populations through a meta-analysis.

Methods

Search methods

We included any RCT assessing antiretroviral drugs to prevent HIV infection in high risk populations. The search terms were “pre-exposure prophylaxis”, “high risk population”, “HIV infection”, “reduction”, “relative risk” and “efficacy”. A comprehensive computerized literature search was carried out in PubMed, EMBase, Ovid, Web of Science, Science Direct, Wan Fang (a Chinese bibliographic database), CNKI (China National Knowledge Infrastructure) and some other websites (ClinicalTrials.gov; hptn.org; Meta-Register) to collect the relevant literature (from establishment to August 2013).

Inclusion criteria

Articles obtained from these searches and relevant references cited in the articles were screened and assessed independently by two reviewers for eligibility. Inclusion criteria were applied to all relevant RCTs as follows: (1) only RCTs evaluating the efficacy of PrEP on HIV infection; (2) studies were high risk HIV-negative people; (3) interventions were daily or intermittent PrEP of single or combined ARVs before HIV exposure or during HIV exposure, both orally and topically; (4) the primary endpoint was new HIV infections.

Exclusion criteria

Studies were excluded if the number of the subjects and events in the experimental group and control group were not well-described. Duplicate publications were also excluded.

Data Extraction

Two reviewers extracted the data of all included trials using a standardized form. Data extracted were as follows: (1) author and publication year; (2) phase of the trial; (3) location and population; (4) enrolment date and follow-up year; (5) interventions; (6) number of participants; (7) endpoints; (8) dropout number in each trial; (9) protection rate or relative risk (RR). If there was different information between two reviewers, the third reviewer would participate to determine the correct information. Additionally, if the data were not sufficient for the meta-analysis, telephone or email was used to get more information.

Assessment of study quality

The methodological quality of the included RCTs was assessed using the standard Jadad score based on the adequacy of randomization, blinding and follow up, with a maximum score of 5 points. A score of 0–2 indicates low quality, while a score of 3–5 indicates high quality [21].

Data synthesis and meta-analysis

Data were analyzed using Stata10.0 software (American Computer Resource Center). We calculated the relative risk (RR) with 95% confidence intervals (CI). Statistical heterogeneity was quantified using the I² statistic to measure the proportion of the overall variation and assessed for strength of the evidence using the chi-squared test [22]. In pooling the data from these included trials, a fixed-effects model was applied using the method of Mantel-Haenzel (M-H) when there was no statistically significant heterogeneity. A random-effects model was employed using the method of DerSimonian and Laird (D+L) if statistically significant heterogeneity was detected. Statistical significance of the test for heterogeneity was set at 0.05. Sensitivity analysis was performed by re-analysis, excluding one low quality study and one study with no statistical significance. A funnel plot was applied to examine the potential publication bias in the meta-analysis. The fail-safe number was calculated as \[ N_{fs} = \left( \frac{Z}{1.64} \right)^2 - k \] [23].

Results

Search results

The detailed search step is summarized in the flow chart (Figure 1). We initially searched 109 citations. After screening and exclusion, thirty-eight articles were further scrutinized. Finally, we identified seven RCTs that meet the inclusion criteria [24–30], including one that was terminated early [29]. Four of the studies [24,26,27,29] were multinational trials. The study of Peterson et al. was conducted in Garna, Cameroon and Nigeria among 936 sexually active women [27]. The study of Grant et al. was conducted in Peru, South Africa, Brazil, Thailand, United States and Ecuador, including 2,499 men who have sex with men (MSM) [26]. The study of Baeren et al. was conducted in Kenya and Uganda among 4,747 HIV-discordant heterosexual couples [24]. The study of Van Damme et al. was conducted in Kenya, South Africa and Tanzania among 2,120 women [29]. The study of Choopanya et al. enrolled 2,413 injecting drug users (IDUs) from drug-treatment clinics in Bangkok, Thailand [30]. The other ten articles were excluded because they are still on-going, duplicate publications, or contain no details about the outcomes [31–40].

Description of included RCTs

Table 1 shows the key characteristics of the included trials. All trials used TDF-containing products, either TDF alone or in combination with FTC. Seven studies were placebo-controlled and one had two intervention groups. Most of the participants lived in highly epidemic HIV areas, such as South Africa, Botswana, Kenya and Uganda. The included trials were reported between 2007 and 2013, and their sample sizes ranged from 889 to 4,747 participants. All 14,804 participants were HIV negative individuals in a high infection risk. Ages ranged from 18–67 years. All the participants provided written informed consent, received HIV testing and were provided with comprehensive HIV prevention services (HIV pre- and post-test counseling, HIV risk reduction counseling, condoms and STI treatment). At the endpoint, five studies showed that PrEP was effective, while the other two did not. The study of Peterson et al. with daily oral 300 mg TDF in Ghana, Nigeria and Cameroon showed no differences in adverse events or grade 3 or 4 laboratory
abnormalities between placebo and TDF users [27]. There were fewer infections in the TDF group (two events versus six events in the placebo group), even though the study was not of sufficient size or duration to examine the efficacy of tenofovir. The study of Van Damme et al. with daily oral TDF/FTC assigned to 2,120 HIV negative women in Kenya, South Africa and Tanzania did not significantly reduce the rate of HIV infection, as compared with the placebo group [29]. HIV infections occurred in thirty-three women in the TDF/FTC group and in thirty-five in the placebo group. The study was stopped early, because of lack of efficacy.

Methodological Quality Assessment
The quality of the included studies is shown in Table 2. All trials were prospective, randomized, double-blinded and placebo-controlled, and were received Jadad scores of 3 (n = 1), 4 (n = 1) or 5 (n = 5) points. All the studies described the baselines in both the experimental and the control groups, and they were similar in important demographic respects. According to the Jadad score, all the studies can be considered high quality research, with scores ≥3.

Meta-analysis
Seven papers describing RCTs were enrolled, including 14,804 subjects in high risk populations. The number of experimental subjects was 8,195, with HIV infection rate of 2.03%. The number of control subjects was 6,609, with HIV infection rate of 4.07%. The result of the heterogeneity test ($X^2 = 11.91$, $P = 0.06 <0.1$, $I^2 = 50\%$) showed that there was heterogeneity among these studies. We therefore chose the random-effects model for the meta-analysis. It showed that the pooled relative risk (RR) was 0.53 (95% CI = 0.40–0.71, $P < 0.001$) (Figure 2).

Sensitivity analysis
There was wide variation in the sample size, the largest study consisted of 4,747 participants (32.1% of the total subjects included in the meta-analysis) and the smallest study consisted of 889 participants. To examine the influence of the largest study on the meta-analysis, we re-analyzed the data by excluding the largest study (which was low in quality). The resulting RR was 0.61 (95% CI = 0.48–0.77), indicating that this study did not largely influence the meta-analysis (Figure 3). In addition, when we excluded the Peterson and Van Damme studies, which had no statistical significance, the RR was 0.49 (95% CI = 0.38–0.63)(Figure 4). The remaining studies,
| Study, year                        | Phase | Location                          | Population                  | Started year (follow-up) | Intervention                                      | Number: infection/total (Experimental) | Number: infection/total (Control) | Protection rate |
|-----------------------------------|-------|-----------------------------------|-----------------------------|--------------------------|--------------------------------------------------|----------------------------------------|----------------------------------|----------------|
| Peterson et al., 2007 [27]       | phase II | Garna, Nigeria, Cameroon            | 936, sexually active women | 2004 (1 y)              | Daily oral 300 mg TDF                            | 2/469                                  | 6/467                           | Protection rate = 65%, P = 0.24 |
| Abdool et al., 2010 [25]         | phase II B | South Africa                      | 889, sexually active women  | 2007 (mean, 1.5 y)       | 40 mg TDF vaginal gel (BAT24)*                    | 38/445                                 | 60/444                          | Protection rate = 39%, (95%CI:6–60%), P = 0.017 |
| Grant et al., 2010 [26]          | phase III | Peru, South Africa, Brazil, Thailand, United States, Ecuador | 2499, MSM                  | 2007 (median, 1.2 y; maximum, 2.8 y) | Daily oral FTC/TDF (200 mg FTC+300 mg TDF)      | 36/1251                                | 64/1248                         | Protection rate = 44%, (95%CI:15–63%), P = 0.0005 |
| Baeten et al., 2011 [24]         | phase III | Kenya, Uganda                      | 4747, HIV-discordant heterosexual couples | 2008 (3 y)              | Daily oral TDF or FTC/TDF (FTC: 200 mg, TDF: 300 mg) | TDF:18/1584; FTC/TDF:13/1579 | 47/1584                        | TDF protection rate = 62%, (95%CI: 34–78%), P = 0.0003; FTC/TDF protection rate = 73%, (95%CI: 49–85%), P < 0.0001 |
| Van Damme et al., 2012 [29]      | phase III | Kenya, South Africa, Tanzania      | 2120, women                | 2009 (1 y)              | Daily oral FTC/TDF (N/A)                          | 33/1062                                | 35/1058                         | Protection rate = 6%, P = 0.81 |
| Thigpen et al., 2011 [28]        | phase II | Botswana                           | 1200, heterosexual men and women | 2007, (median, 1.1 y; maximum, 3.7 y) | Daily oral FTC/TDF (N/A)                          | 9/601                                  | 24/599                          | Protection rate = 62.6%, (95%CI:21.5–83.4%), P = 0.003 |
| Choopanya et al., 2013 [30]      | phase III | Bangkok, Thailand                  | 2413, IDUs                 | 2005, (median, 40 y; maximum, 69 y) | Daily oral 300 mg TDF                            | 17/1204                                | 33/1209                         | Protection rate = 48.9%, (95%CI: 9.6–72.2%), P = 0.01 |

Note: MSM, men who have sex with men; IDUs, injecting drug users; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate; PR, Protection Rate; CI, 95% confidence intervals; BAT24, one dose of tenofovir gel within 12 hours before sex and a second dose within 12 hours after sex; N/A, not available.
doi:10.1371/journal.pone.0087674.t001
after excluding the largest study and two without statistical significance, produced results similar to the overall meta-analysis.

**Publication bias**

A funnel plot of the data is presented in Figure 5. The included studies appear in the funnel plot completely and are distributed around the pooled RR, with large sample size results at the top. Meantime, we performed funnel chart linear regression model analysis. The result showed that the intercept’s 95% CI = -3.14 ± 1.93 contained 0 ($P=0.565>0.1$), indicating that the funnel plot was symmetrical. The fail-safe number of this study was 1,022, which means that it would need at least 1,022 unpublished, especially negative results in the literature to override the conclusion of the meta-analysis.

**Discussion**

This meta-analysis provides evidence that PrEP is associated with a reduced risk of HIV infection in high risk populations. The strongest association was seen in the Thigpen study, with a protective rate of 62.6% in HIV-uninfected, sexually active, healthy males and females. As a new prevention method, antiretroviral drugs effectively prevent HIV transmission at birth, during breastfeeding and after occupational exposure [41,42]. Proof-of-concept that PrEP protects against sexual HIV acquisition has been demonstrated in clinical trials. Nowadays, PrEP is still in the clinical trial phases, and large phase III clinical randomized controlled trials are ongoing.

There are several strengths and limitations to consider in our analysis and in the included trials. The strengths of our meta-analysis include two extensive studies (with a sample size more than two thousand subjects), thirteen different sites (Gambia, Cameroon, Nigeria, South Africa, Peru, Brazil, Thailand, United States, Ecuador, Botswana, Kenya, Uganda and Tanzania).

---

**Table 2. Quality assessment of the included trials.**

| Study, year       | Randomization | Blinding     | Placebo-controlled | Dropout (n) | Jadad score |
|-------------------|---------------|--------------|--------------------|-------------|-------------|
| Peterson et al., 2007 | adequate      | double-blind | yes                | 162         | 5           |
| Abdool et al., 2010  | unclear       | double-blind | yes                | 6           | 4           |
| Grant et al., 2010  | adequate      | double-blind | yes                | 48          | 5           |
| Baeten et al., 2011 | unclear       | double-blind | yes                | N/A         | 3           |
| Van Damme et al., 2012 | adequate     | double-blind | yes                | 266         | 5           |
| Thigpen et al., 2012 | adequate      | double-blind | yes                | 115         | 5           |
| Choopanya et al., 2013 | adequate   | double-blind | yes                | 355         | 5           |

Note: Adequate if the allocation sequence was generated by a computer or random number table. Unclear if the trial was described as randomized, but the method used for the allocation sequence generation was not described; N/A, not available.

doi:10.1371/journal.pone.0087674.t002

**Figure 2. Random-effects model meta-analysis.** Heterogeneity chi-squared = 11.91 (d.f. = 6), $P=0.064$; test of RR = 1 z = 4.29, $P<0.001$.

doi:10.1371/journal.pone.0087674.g002
Figure 3. Random-effects model meta-analysis excluding the largest study. Heterogeneity chi-squared = 5.95 (d.f. = 5), \( P = 0.311 \); test of RR = 1: \( z = 4.12 \), \( P < 0.001 \).
doi:10.1371/journal.pone.0087674.g003

Figure 4. Random-effects model meta-analysis, excluding two studies with no statistical significance. Heterogeneity chi-squared = 5.58 (d.f. = 4), \( P = 0.233 \); test of RR = 1: \( z = 5.51 \), \( P < 0.001 \).
doi:10.1371/journal.pone.0087674.g004
and different HIV high risk populations (MSM, IDUs, HIV-discordant heterosexual couples and heterosexual men and women).

Perhaps the most important limitation of our meta-analysis is the small number of studies available to fully explore how PrEP prevents the acquisition of HIV infection in high risk populations. The analysis of these RCTs was restricted to a part of high risk populations. Other ongoing clinical trials on oral or topical HIV PrEP including other high risk populations have no results reported yet [43].

The second limitation to the result was that two studies were stopped early for some reasons. One phase II safety study in Ghana, Nigeria and Cameroon among 936 female sex workers showed no difference in the frequency of adverse events between those taking tenofovir and placebo. The initial results of this study did not show a good prophylactic effect, and this trial was not completed as planned. Two sites (Nigeria and Cameroon) were closed either before the planned number of participants had been recruited or before all participants had completed full follow-up. Therefore, this study did not have sufficient power to assess the differences between trial arms in the primary efficacy analysis. Moreover, the study of Van Damme et al. showed that prophylaxis with TDF/FTC did not significantly reduce the rate of HIV infection. It was stopped early, because of lack of efficacy, and with 13% participants lost to follow-up.

The third limitation of the literature was the different formulations and dosages of antiretroviral drugs in the included trials. In Peterson and Choopanya studies, participants were randomized to once daily use of 300 mg of TDF or placebo. In Grant, Van Damme and Thigpen studies, participants were randomized to once daily use of FTC/TDF (200 mg FTC+300 mg TDF) or placebo. In study of Abdool et al., women applied one dose of tenofovir gel within 12 hours before sex and a second dose of tenofovir gel as soon as possible within 12 hours after sex, but no more than two doses of tenofovir gel in 24-hour period. In study of Backet et al., participants were randomized to a three-arm trial of once daily use of TDF, FTC/TDF or placebo.

The fourth limitation was that there are several areas that require further research and on-going surveillance if PrEP is to become part of an HIV prevention program. It is impossible for PrEP to provide 100% protection against HIV, and some people will become infected while using PrEP. Furthermore, this may help the virus to mutate, resulting in restricted future treatment options. Moreover, informal drug sharing, black-market use or imperfect screening might result in some people who are HIV-positive inadvertently taking prophylaxis.

The final limitation was that only articles in English were included, so there might be a language bias.

The available relevant studies were included in our meta-analysis. Our findings support that PrEP has protective effect against HIV infection in high risk populations. If other on-going and large scale studies provide more data on the relationship between PrEP and HIV infection in coming years, it will help to further define the role of PrEP in the prevention of HIV transmission. However, as a strategy, PrEP should always be regarded as a component of prevention but not a replacement for existing methods, and should be integrated as much as possible into existing programs to bring us closer to our goal of full prevention.

**Supporting Information**

Table S1 PRISMA Checklist

**Acknowledgments**

We thank Dr. Yiming Shao at National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention, Beijing, China for their contribution to the project.

**Author Contributions**

Conceived and designed the experiments: JJ XY XZ AH HL. Performed the experiments: JJ BZ BL CC RT HC. Analyzed the data: XY CN JH. Wrote the paper: JJ XY LY.

---

**Figure 5. Funnel plot for the publication bias of all seven included trials.**

doi:10.1371/journal.pone.0087674.g005
References

1. Global report: UNAIDS report on the global AIDS epidemic 2012. UNAIDS website. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_with_annexes_en.pdf. Accessed 13 Oct. 2016.

2. D’Cruz OJ, Uckun FM (2006) Novel broad-spectrum thiosulfate non-nucleoside inhibitors for the prevention of mucosal HIV transmission. Curr HIV Res 6: 329–345.

3. Hirbut T, Brodkin K (2007) Mucosal immune responses in the genital tract of HIV-1-infected uninfected women. J Interm Med 262: 44–36.

4. Kim SC, Becker S, Deifelbach C, Haneswall BS, Hankins C, et al. (2010) Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc 13: 24.

5. Padian NS, Bale A, Ballaux J, Serwaad D, Cates W (2008) HIV prevention 2 - Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 372: 583–599.

6. Grant RM, Buchbinder S, Cates W, Clarke E, Cong ME, et al. (2008) Prevention of rectal infection. Plos Medicine 5: e28.

7. Li Q, Estes JD, Schlevert PM, Duan L, Broussahal AF, et al. (2009) Glycerol monolaurate prevents mucosal SIV transmission. Nature 458: 1034–1038.

8. Yule M, Wainberg MA (2003) Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? AIDS 17: 937–938.

9. Paxton L (2007) Narrative review: antiretroviral prophylaxis research, don't prevent it. The Journal of Evidence-Based Medicine 6: 297–303.

10. Thigpen MC, Kafulafula G, et al. (2008) Effectiveness of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate, and Emtricitabine/Tenofovir Disproxil Fumarate Tablets in Preventing HIV in Women.

11. Grant RM Use of Emtricitabine and Tenofovir Disproxil Fumarate for Pre-Exposure Prophylaxis (ADAPT).

12. Evaluating the Safety and Tolerability of Antiretroviral Pre-exposure Prophylaxis to Prevent HIV Infection in Men Who Have Sex With Men (HEPOT 009).

13. Paltiel AD, Freedberg KA, Schackman BR, Losina E, et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 49: 806–815.

14. Okwundu CI, Uthman OA, Okoromah CA (2012) Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev 7: CD007189.

15. Li Q, Estes JD, Schlevert PM, Du L, Broussahan AF, et al. (2009) Glycerol monolaurate prevents mucosal SIV transmission. Nature 458: 1034–1038.

16. Thigpen MC, Kebaabetswe PM, Smith DK, Segolodi TM, Soul AF, et al. (2011) Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention Rome.

17. 23. MAI Jinzhuang, LI He, FANG Jiqian, et al (2006) Re: Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Men. J Urol 185: 1729.

18. Kumwenda NI, Hoover DR, Losina E, et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 49: 806–815.

19. Okwundu CI, Uthman OA, Okoromah CA (2012) Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev 7: CD007189.

20. Okwundu CI, Uthman OA, Okoromah CA (2012) Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev 7: CD007189.

21. Thigpen MC, Kafulafula G, et al. (2008) Effectiveness of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate, and Emtricitabine/Tenofovir Disproxil Fumarate Tablets in Preventing HIV in Women.

22. Grant RM Use of Emtricitabine and Tenofovir Disproxil Fumarate for Pre-Exposure Prophylaxis (ADAPT).

23. Evaluating the Safety and Tolerability of Antiretroviral Pre-exposure Prophylaxis to Prevent HIV Infection in Men Who Have Sex With Men (HEPOT 009).

24. Paltiel AD, Freedberg KA, Schackman BR, Losina E, et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 49: 806–815.

25. Okwundu CI, Uthman OA, Okoromah CA (2012) Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev 7: CD007189.

26. Thigpen MC, Kebaabetswe PM, Smith DK, Segolodi TM, Soul AF, et al. (2011) Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention Rome.

27. Abril-de Gracia C, Bellov AC, Cengotti B, et al. (2009) Characteristics of HIV-1 prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials 12: 67.

28. Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Chuachoo Wong R, et al. (2011) Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials 12: 67.

29. Mutua G, Sanders E, Mugo N, Anzala P, Mugo NR, et al. (2011) Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One 6: e23828.

30. Muasa G, Sanders E, Mugo NR, Anzala P, Mugo NR, et al. (2011) Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One 6: e23828.

31. Kumwenda NI, Hoover DR, Losina E, et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 49: 806–815.

32. Chirenje ZM, Marrazzo JM (2012) Safety and Effectiveness of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate, and Emtricitabine/Tenofovir Disproxil Fumarate Tablets in Preventing HIV in Women.

33. Grant RM Use of Emtricitabine and Tenofovir Disproxil Fumarate for Pre-Exposure Prophylaxis (ADAPT).

34. Evaluating the Safety and Tolerability of Antiretroviral Pre-exposure Prophylaxis to Prevent HIV Infection in Men Who Have Sex With Men (HEPOT 009).

35. The Journal of Evidence-Based Medicine 6: 297–303.

36. Berger RE (2011) Re: Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Men. J Urol 185: 1729.

37. Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende S, et al. (2011) Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials 12: 67.

38. Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Chuachoo Wong R, et al. (2011) Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study. Thailand. PLoS One 6: e23127.

39. Kumwenda NI, Hoover DR, Losina E, et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 49: 806–815.

40. Thigpen MC, Kebaabetswe PM, Smith DK, Segolodi TM, Soul AF, et al. (2011) Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention Rome.

41. Abril-de Gracia C, Bellov AC, Cengotti B, et al. (2009) Characteristics of HIV-1 prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials 12: 67.

42. Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Chuachoo Wong R, et al. (2011) Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials 12: 67.

43. Kumwenda NI, Hoover DR, Losina E, et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 49: 806–815.

44. Berger RE (2011) Re: Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Men. J Urol 185: 1729.